GSK, BioMerieux to Develop, Globally Launch Predictive Breast Cancer Dx to Guide Treatment

GSK's deal with the French firm suggests the pharma giant favors partnerships with diagnostics companies that have large global networks to facilitate the global launch of the drug and diagnostic.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories